Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Low-Dose and Long-Term Olaparib Treatment Sensitizes MDA-MB-231 and SUM1315 Triple-Negative Breast Cancers Spheroids to Fractioned Radiotherapy.

Dubois C, Martin F, Hassel C, Magnier F, Daumar P, Aubel C, Guerder S, Mounetou E, Penault-Lorca F, Bamdad M.

J Clin Med. 2019 Dec 26;9(1). pii: E64. doi: 10.3390/jcm9010064.

2.

The New Synthetic Serum-Free Medium OptiPASS Promotes High Proliferation and Drug Efficacy Prediction on Spheroids from MDA-MB-231 and SUM1315 Triple-Negative Breast Cancer Cell Lines.

Dubois C, Daumar P, Aubel C, Gauthier J, Vidalinc B, Mounetou E, Penault-Llorca F, Bamdad M.

J Clin Med. 2019 Mar 21;8(3). pii: E397. doi: 10.3390/jcm8030397.

3.

Development and cytotoxic response of two proliferative MDA-MB-231 and non-proliferative SUM1315 three-dimensional cell culture models of triple-negative basal-like breast cancer cell lines.

Dubois C, Dufour R, Daumar P, Aubel C, Szczepaniak C, Blavignac C, Mounetou E, Penault-Llorca F, Bamdad M.

Oncotarget. 2017 Aug 24;8(56):95316-95331. doi: 10.18632/oncotarget.20517. eCollection 2017 Nov 10.

4.

Anti-EGFR monoclonal antibodies enhance sensitivity to DNA-damaging agents in BRCA1-mutated and PTEN-wild-type triple-negative breast cancer cells.

El Guerrab A, Bamdad M, Bignon YJ, Penault-Llorca F, Aubel C.

Mol Carcinog. 2017 May;56(5):1383-1394. doi: 10.1002/mc.22596. Epub 2017 Mar 6.

PMID:
27864890
5.

Anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors as combination therapy for triple-negative breast cancer.

El Guerrab A, Bamdad M, Kwiatkowski F, Bignon YJ, Penault-Llorca F, Aubel C.

Oncotarget. 2016 Nov 8;7(45):73618-73637. doi: 10.18632/oncotarget.12037.

6.

BCRP and P-gp relay overexpression in triple negative basal-like breast cancer cell line: a prospective role in resistance to Olaparib.

Dufour R, Daumar P, Mounetou E, Aubel C, Kwiatkowski F, Abrial C, Vatoux C, Penault-Llorca F, Bamdad M.

Sci Rep. 2015 Aug 3;5:12670. doi: 10.1038/srep12670.

7.

BRCA1 induces major energetic metabolism reprogramming in breast cancer cells.

Privat M, Radosevic-Robin N, Aubel C, Cayre A, Penault-Llorca F, Marceau G, Sapin V, Bignon YJ, Morvan D.

PLoS One. 2014 Jul 10;9(7):e102438. doi: 10.1371/journal.pone.0102438. eCollection 2014.

8.

AKT and p21 WAF1/CIP1 as potential genistein targets in BRCA1-mutant human breast cancer cell lines.

Privat M, Aubel C, Arnould S, Communal Y, Ferrara M, Bignon YJ.

Anticancer Res. 2010 Jun;30(6):2049-54.

PMID:
20651350
9.

Breast cancer cell response to genistein is conditioned by BRCA1 mutations.

Privat M, Aubel C, Arnould S, Communal Y, Ferrara M, Bignon YJ.

Biochem Biophys Res Commun. 2009 Feb 13;379(3):785-9. doi: 10.1016/j.bbrc.2008.12.151. Epub 2009 Jan 4.

PMID:
19126406
10.

Cidofovir administered with radiation displays an antiangiogenic effect mediated by E6 inhibition and subsequent TP53-dependent VEGF repression in HPV18+ cell lines.

Amine A, Vozenin-Brotons MC, Abdulkarim B, Violot D, Aubel C, Bourhis J.

Radiat Res. 2006 Oct;166(4):600-10.

PMID:
17007547
11.

Therapeutic protein transduction of mammalian cells and mice by nucleic acid-free lentiviral nanoparticles.

Link N, Aubel C, Kelm JM, Marty RR, Greber D, Djonov V, Bourhis J, Weber W, Fussenegger M.

Nucleic Acids Res. 2006 Jan 30;34(2):e16.

12.

Ornithine decarboxylase activity is inhibited by the polyamine precursor amino acids at the protein stability level in Caco-2 cells.

Chabanon H, Aubel C, Larvaron P, Villard C, Carraro V, Brachet P.

Biochim Biophys Acta. 2005 May 25;1723(1-3):74-81. Epub 2005 Jan 22.

PMID:
15716048
13.

Expression of spermidine/spermine N1-acetyltransferase in HeLa cells is regulated by amino acid sufficiency.

Aubel C, Chabanon H, Carraro V, Wallace HM, Brachet P.

Int J Biochem Cell Biol. 2003 Sep;35(9):1388-98.

PMID:
12798351

Supplemental Content

Loading ...
Support Center